Glenmark Specialty SA has received US FDA approval for its Fluticasone Propionate inhalation aerosol, securing 180-day competitive generic therapy exclusivity in a market with annual sales of over $520 million.
Glenmark Specialty SA has received US FDA approval for its Fluticasone Propionate inhalation aerosol, securing 180-day competitive generic therapy exclusivity in a market with annual sales of over $520 million.